Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The PEP-TALK trial has been given the green light and is now open to recruitment.

The PEP-TALK Trial has opened to recruitment.

 

PEP-TALK is a multi-centre randomised controlled trial to assess the effectiveness of a group exercise and behaviour-change intervention to increase physical activity in people following a Total Hip Replacement or a Total Knee Replacement. Half the patients involved in the trial will receive the normal rehabilitation after hip or knee replacement which is attendance to 6 exercise group sessions provided weekly from up to 4 weeks after the operation. The other half of patients involved in the trial will receive this plus 6, 30-minute group discussions, where patients will be supported to talk about what helps or hinders them being more physically active and to work out ways which may help them become more active in their recovery.

 

Further information can be found on the trial website: https://peptalk.octru.ox.ac.uk/

Similar stories

Emergency to use the FORCE pathway for wrist fractures in children

New research from the University of Oxford has shown that doctors can simplify treatment for the most common fracture in children, reducing NHS costs.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.